12/19/2025

[Duplicate] Prices Set for the Second Round of Drugs Included in the Medicare Drug Price Negotiation Program  

CMS has concluded the second round of price negotiations for fifteen Part D drugs with the newly negotiated prices effective January 1, 2027. The list includes two drugs used to treat hematologic cancers. Pomalidomide, used to treat multiple myeloma, and acalabrutinib, used to treat leukemia and lymphoma, will see significant price reductions for a 30-day supply. The pomalidomide list price will be reduced by 60% from $21,744 to $8,650 and the acalabrutinib will see a reduction of 40% from $14,228 to $8,600. A complete list of the drugs, prices and cost savings can be found here: 2027 Part D negotiated drug prices.